Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial
Journal of Infection · 2023
DOI: 10.1016/j.jinf.2023.06.007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Infection, 2023. Verfasst von Eimear Kelly und 33 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health.
Abstract (Originalsprache)
BACKGROUND: This was the first study to investigate the reactogenicity and immunogenicity of heterologous or fractional second dose COVID-19 vaccine regimens in adolescents. METHODS: A phase II, single-blind, multi-centre, randomised-controlled trial recruited across seven UK sites from September to November 2021, with follow-up visits to August 2022. Healthy 12-to-16 years olds were randomised (1:1:1) to either 30 µg BNT162b2 (BNT-30), 10 µg BNT162b2 (BNT-10), or NVX-CoV2373 (NVX), 8 weeks after a first 30 µg dose of BNT162b2. The primary outcome was solicited systemic reactions in the week following vaccination. Secondary outcomes included immunogenicity and safety. 'Breakthrough infection' analyses were exploratory. FINDINGS: 148 participants were recruited (median age 14 years old, 62% female, 26% anti-nucleocapsid IgG seropositive pre-second dose); 132 participants received a second dose. Reactions were mostly mild-to-moderate, with lower rates in BNT-10 recipients. No vaccine-related serious adverse events occurred. Compared to BNT-30, at 28 days post-second dose anti-spike antibody responses were similar for NVX (adjusted geometric mean ratio [aGMR]) 1.09 95% confidence interval (CI): 0.84, 1.42] and lower for BNT-10 (aGMR 0.78 [95% CI: 0.61, 0.99]). For Omicron BA.1 and BA.2, the neutralising antibody titres for BNT-30 at day 28 were similar for BNT-10 (aGMR 1.0 [95% CI: 0.65, 1.54] and 1.02 [95% CI: 0.71, 1.48], respectively), but higher for NVX (aGMR 1.7 [95% CI: 1.07, 2.69] and 1.43 [95% CI: 0.96, 2.12], respectively). Compared to BNT-30, cellular immune responses were greatest for NVX (aGMR 1.73 [95% CI: 0.94, 3.18]), and lowest for BNT-10 (aGMR 0.65 [95% CI: 0.37, 1.15]) at 14 days post-second dose. Cellular responses were similar across the study arms by day 236 post-second dose. Amongst SARS-CoV-2 infection naïve participants, NVX participants had an 89% reduction in risk of self-reported 'breakthrough infection' compared to BNT-30 (adjusted hazard ratio [aHR] 0.11 [95% CI: 0.01, 0.86]) up until day 132 after second dose. BNT-10 recipients were more likely to have a 'breakthrough infection' compared to BNT-30 (aHR 2.14 [95% CI: 1.02, 4.51]) up to day 132 and day 236 post-second dose. Antibody responses at 132 and 236 days after second dose were similar for all vaccine schedules. INTERPRETATION: Heterologous and fractional dose COVID-19 vaccine schedules in adolescents are safe, well-tolerated and immunogenic. The enhanced performance of the heterologous schedule using NVX-CoV2373 against the Omicron SARS-CoV-2 variant suggests this mRNA prime and protein-subunit boost schedule may provide a greater breadth of protection than the licensed homologous schedule. FUNDING: National Institute for Health Research and Vaccine Task Force. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number registry: 12348322.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, Department of Paediatrics, University of Oxford, Oxford, UK.
- NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of South…
- Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, UK.
- Health Protection Scotland, Glasgow, UK.
- University of Nottingham, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK.
- Vaccine Institute, St. George's, University of London and St. George's University Hospitals NHS Trust, London, UK.
Förderung
- Department of Health
Zitieren
APA
Kelly, E., Greenland, M., de Whalley, P. C. S., Aley, P. K., Plested, E. L., Singh, N., Koleva, S., Tonner, S., Macaulay, G. C., Read, R. C., Ramsay, M., Cameron, J. C., Turner, D. P. J., Heath, P. T., Bernatoniene, J., Connor, P., Cathie, K., Faust, S. N., Banerjee, I., …, & Com-COV3 Study Group (2023). Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial. Journal of Infection. https://doi.org/10.1016/j.jinf.2023.06.007
Vancouver
Kelly E, Greenland M, de Whalley PCS, Aley PK, Plested EL, Singh N, et al. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial. Journal of Infection. 2023. doi:10.1016/j.jinf.2023.06.007
BibTeX
@article{Kelly2023,
author = {Kelly, Eimear and Greenland, Melanie and de Whalley, Philip C S and Aley, Parvinder K and Plested, Emma L and Singh, Nisha and Koleva, Stanislava and Tonner, Sharon and Macaulay, Grace C and Read, Robert C and Ramsay, Mary and Cameron, J Claire and Turner, David P J and Heath, Paul T and Bernatoniene, Jolanta and Connor, Philip and Cathie, Katrina and Faust, Saul N and Banerjee, Indraneel and Cantrell, Liberty and Mujadidi, Yama F and Belhadef, Hanane Trari and Clutterbuck, Elizabeth A and Anslow, Rachel and Valliji, Zara and James, Tim and Hallis, Bassam and Otter, Ashley David and Lambe, Teresa and Nguyen-Van-Tam, Jonathan S and Minassian, Angela M and Liu, Xinxue and Snape, Matthew D and Com-COV3 Study Group, Com-COV3 Study Group},
title = {Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial},
journal = {Journal of Infection},
year = {2023},
doi = {10.1016/j.jinf.2023.06.007}
}
EUVIMED